Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients

NCT04620304 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

BIOLOGICAL: UB-421 SC(dB4C7C22-6 mAb)

Sponsor

United BioPharma

Collaborators

[object Object]
[object Object]
[object Object]